Tesaro Inc. (Nasdaq: TSRO) reported positive results from a Phase 3 NOVA trial of niraparib to treat ovarian cancer sending the stock price soaring $40.19 to close at $77.40.
Tesaro reports positive test results
June 29, 2016 at 16:49 PM EDT
Tesaro reports positive test resultsJune 29, 2016 at 16:49 PM EDT
Tesaro Inc. (Nasdaq: TSRO) reported positive results from a Phase 3 NOVA trial of niraparib to treat ovarian cancer sending the stock price soaring $40.19 to close at $77.40. Related Stocks:
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|